Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 10/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.53 |
| ▸ | WNT1 | P04628 | 3/20 | 0.52 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | HTR1F | P30939 | 1/20 | 0.51 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676896 | 1.00 | PIK3C3 (0.56) | PIK3C3GSK3BDYRK1AWNT1PIP5K1C | |
| SCHEMBL15542212 | 0.88 | ABL1 (0.62) | PIK3C3GSK3BABL1ACVRL1 | |
| SCHEMBL25131736 | 0.86 | PIK3C3 (0.46) | PIK3C3GSK3BDYRK1AWNT1PIP5K1C | |
| SCHEMBL25131231 | 0.86 | PIK3C3 (0.49) | PIK3C3GSK3BDYRK1AWNT1PIP5K1C | |
| SCHEMBL23893005 | 0.85 | ABL1 (0.56) | PIK3C3GSK3BABL1ACVRL1 | |
| SCHEMBL20053909 | 0.84 | PIK3C3 (0.57) | PIK3C3GSK3BDYRK1AWNT1PIP5K1C | |
| SCHEMBL18640001 | 0.84 | ABL1 (0.55) | PIK3C3GSK3BABL1ACVRL1 | |
| SCHEMBL4339961 | 0.83 | ALDH1A1 (0.60) | PIK3C3GSK3BDYRK1AWNT1PIP5K1C | |
| SCHEMBL17632556 | 0.83 | MAPK8 (0.52) | PIK3C3GSK3BABL1MAPK8MAPK10 | |
| SCHEMBL17631632 | 0.83 | MAPK8 (0.52) | PIK3C3GSK3BABL1MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | disclosed |
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-18 | — | — | US | disclosed |
| EP-4182308-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-10-20 | — | — | US | disclosed |
| CN-109096274-B | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022013307-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-01-20 | — | — | WO | disclosed |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | BIOGEN MA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3357921-A2 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Sunesis Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3080103-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | PIK3C3 38/4885GSK3B 86/4885DYRK1A 216/4885 |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | ABL1, BTK, LYN | PIK3C3 38/4885GSK3B 86/4885DYRK1A 216/4885 |
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | PIK3C3 2381/4885GSK3B 236/4885DYRK1A 2431/4885 |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | PIK3C3 38/4885GSK3B 86/4885DYRK1A 216/4885 |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | PIK3C3 38/4885GSK3B 86/4885DYRK1A 216/4885 |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | PIK3C3 38/4885GSK3B 86/4885DYRK1A 216/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | PIK3C3 2381/4885GSK3B 236/4885DYRK1A 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.